Literature DB >> 12893276

Differential binding properties of B7-H1 and B7-DC to programmed death-1.

Pornpan Youngnak1, Yuko Kozono, Haruo Kozono, Hideyuki Iwai, Noriko Otsuki, Hisayo Jin, Ken Omura, Hideo Yagita, Drew M Pardoll, Lieping Chen, Miyuki Azuma.   

Abstract

Programmed death-1 (PD-1) is a negative regulatory receptor expressed on activated T and B cells. Two ligands for PD-1, B7-H1 (PD-L1) and B7-DC (PD-L2), have been identified, but their binding properties have not been characterized yet. In this study, we generated soluble Ig fusion proteins of these molecules and examined the kinetics and relative affinities of the interactions between B7-H1 or B7-DC and PD-1 by flow cytometry and surface plasmon resonance. The interaction of B7-DC/PD-1 exhibited a 2-6-fold higher affinity and had different association/dissociation kinetics compared with the interaction of B7-H1/PD-1. Our results suggest that the differential binding properties of B7-H1 and B7-DC may be responsible for differential contributions of these two PD-1 ligands to immune responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12893276     DOI: 10.1016/s0006-291x(03)01257-9

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  64 in total

Review 1.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

2.  PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1.

Authors:  Marguerite Ghiotto; Laurent Gauthier; Nacer Serriari; Sonia Pastor; Alemseged Truneh; Jacques A Nunès; Daniel Olive
Journal:  Int Immunol       Date:  2010-06-29       Impact factor: 4.823

Review 3.  The balance of immune responses: costimulation verse coinhibition.

Authors:  Sumit K Subudhi; Maria-Luisa Alegre; Yang-Xin Fu
Journal:  J Mol Med (Berl)       Date:  2005-01-04       Impact factor: 4.599

4.  Expression of PD-L1 and PD-L2 on human macrophages is up-regulated by HIV-1 and differentially modulated by IL-10.

Authors:  Marta Rodríguez-García; Filippos Porichis; Olivier G de Jong; Karen Levi; Thomas J Diefenbach; Jeffrey D Lifson; Gordon J Freeman; Bruce D Walker; Daniel E Kaufmann; Daniel G Kavanagh
Journal:  J Leukoc Biol       Date:  2010-11-19       Impact factor: 4.962

5.  Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability.

Authors:  Tsvetelina Pentcheva-Hoang; Lieping Chen; Drew M Pardoll; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-29       Impact factor: 11.205

Review 6.  Checkpoint blockade in cancer immunotherapy.

Authors:  Alan J Korman; Karl S Peggs; James P Allison
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

Review 7.  The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Authors:  Kathleen M Mahoney; Gordon J Freeman; David F McDermott
Journal:  Clin Ther       Date:  2015-03-29       Impact factor: 3.393

Review 8.  Targeting the B7 family of co-stimulatory molecules: successes and challenges.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  BioDrugs       Date:  2013-02       Impact factor: 5.807

9.  Tumour CD274 (PD-L1) expression and T cells in colorectal cancer.

Authors:  Yohei Masugi; Reiko Nishihara; Juhong Yang; Kosuke Mima; Annacarolina da Silva; Yan Shi; Kentaro Inamura; Yin Cao; Mingyang Song; Jonathan A Nowak; Xiaoyun Liao; Katsuhiko Nosho; Andrew T Chan; Marios Giannakis; Adam J Bass; F Stephen Hodi; Gordon J Freeman; Scott Rodig; Charles S Fuchs; Zhi Rong Qian; Shuji Ogino
Journal:  Gut       Date:  2016-05-05       Impact factor: 23.059

10.  Interaction of human PD-L1 and B7-1.

Authors:  Manish J Butte; Victor Peña-Cruz; Mi-Jung Kim; Gordon J Freeman; Arlene H Sharpe
Journal:  Mol Immunol       Date:  2008-06-27       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.